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ABSTRACT
We analyse the system of ethical review of human
research in the Baltic States by introducing the principle
of equivalent stringency of ethical review, that is,
research projects imposing equal risks and
inconveniences on research participants should be
subjected to equally stringent review procedures. We
examine several examples of non-equivalence or
asymmetry in the system of ethical review of human
research: (1) the asymmetry between rather strict
regulations of clinical drug trials and relatively weaker
regulations of other types of clinical biomedical research
and (2) gaps in ethical review in the area of non-
biomedical human research where some sensitive
research projects are not reviewed by research ethics
committees at all. We conclude that non-equivalent
stringency of ethical review is at least partly linked to the
differences in scope and binding character of various
international legal instruments that have been shaping
the system of ethical review in the Baltic States.
Therefore, the Baltic example could also serve as an
object lesson to other European countries which might
be experiencing similar problems.
In some countries, variations of procedural strin-
gency of ethical review may reflect an underdevel-
oped infrastructure of research ethics committees
(RECs) where their approval is seen simply as a
formality to comply with the requirements of
international partners.1 Such RECs function as a
“rubber stamp” to legitimise research and become,
in the words of Richard Ashcroft, a “figleaf”
covering institutions not able to perform their
mission of protecting the interests of research
subjects.2 However, much more complex issues of
varying stringency of ethical review stem from
some systematic asymmetries in the research
regulations. We analyse asymmetries or cases of
non-equivalent stringency of ethical review in the
Baltic States of Estonia, Latvia and Lithuania that
recently attempted to build within a rather short
time span a research ethics review system based on
international instruments and regulations. Since
the early attempts in the late 1980s, when first
RECs were established as a result of local initiatives
in particular research institutions, ethical review of
human research in these countries has undergone
significant change influenced by a series of legal and
institutional developments. Estonia has chosen the
simplest system of ethical review with two RECs
based in two main medical research institutions of
the country. Lithuania has developed a two-tier
system of ethical review that includes the National
Bioethics Committee issuing approvals for multi-
centre biomedical research studies and two regional
RECs. Latvia followed the most diverse path
establishing nine different RECs that vary in their
institutional affiliation and types of protocols
reviewed. Detailed description of RECs in the Baltic
States can be found in the study of Dranseika et al.3
However, despite the attempts to establish
a balanced system of ethical review and mentioned
differences between institutional structures of ethical
review in the Baltic States, some common problems
could still be observed. In this paper, we analyse three
different types of non-equivalence or asymmetry
where research of comparable risk and burden fail to
achieve similar procedural scrutiny of ethical review.
EQUIVALENCE OF THE PROCEDURES OF ETHICAL
REVIEW
The system of ethical review of human research is
based on the idea that research projects imposing
equal or similar amount of risks and inconveniences
on research participants should be subjected to
equally or similarly stringent review procedures. We
call it the principle of equivalent stringency of
ethical review. This principle can be applied to
types of research or to particular research projects.
David Hunter recently formulated a version of this
principle applicable to particular research projects
(which he categorised as “proportional ethics
review”) in the following way: “the level of ethical
review and scrutiny given to a research project
ought to reflect the level of ethical risk represented
by that project” (p. 241).4 However, he was critical
of the principle on grounds that even if it is intui-
tively appealing, it is impracticable. We agree with
Hunter ’s conclusions; therefore, in this paper, we
will be concerned with this principle only as it
relates to the types of research.
To sum up, the principle of equivalent stringency
justifies varying degrees of procedural stringency of
ethical review. The riskier and more burdensome
a particular type of human research is, the stricter
the requirements of ethical review should be. By
the same token, if two types of research are similar
in risks and burdens, there is a good reason to apply
procedures of similar stringency.
The principle is intuitively appealing and may
also serve as a device to diagnose inconsistencies
inherent in the system. First, gaps of ethical review
where some types of human research involving
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risks are excluded from ethical review altogether indicate that
system is not well-balanced and that research participants are
not sufficiently protected. Since the main mission of RECs is
protection of welfare and interests of research participants, gaps
are worrisome.
The more complex cases of non-equivalent stringency are
asymmetries between procedural stringency of ethical review of
different types of human research that involve similar level of
risks, for example, the asymmetry between review of clinical drug
trials and other types of clinical research. In this case, the
equivalence might not be a problem from the point of view of
research participants because they need only to be assured that
research in which they participate will be subjected to sufficient
ethical scrutiny. On the other hand, for other stakeholders
involved in human research, non-equivalence may be problematic.
Anything above sufficiency level places unnecessary burden on
researchers, sponsors (stricter review may delay approval and
increase ethical review fees) and society as a whole. Larger ethics
review infrastructure may divert resources from potentially more
useful endeavours. The development of science and medicine and
the economic benefits produced by pharmaceutical industry are
the other values that should also not be ignored. The principle
of equivalent stringency of ethical review helps recognise the
interests of various stakeholders involved in research.
In addition, non-equivalencedrandomness between levels of
depth of reviewdproduces the appearance of incoherence,
potentially damaging to society ’s confidence in the system.
Adherence to the principle of equivalence should help to create a
more coherent and predictable system.
In this paper, we do not aim to define sufficient levels of ethical
scrutiny for different types of research nor do we intend to
provide an analysis of “sufficiency”. However, we can stipulate
a formal requirement that if a certain level of ethical scrutiny is
regarded as sufficient (insufficient) by research participants (and
RECs since one of their functions is to protect interests of the
research participants) for a certain type of research, then the same
level of scrutiny should be considered sufficient (insufficient) for
some other type of research which is equal in risks to the first one.
It is important to note, however, that cases of non-equivalence
can be identified even if one does not have a way to tell what level
of procedural stringency would be adequate for a particular type
of research. Our goal is quite modest: we do not aim to solve the
problem of procedural stringency in relation to every single
research project but rather try to show that there are systematic
asymmetries related to the types of research as they are usually
defined in international normative documents defining the
procedures of ethical review. For the purposes of this paper, we
will also limit our discussion to the “procedural” framework of
ethical review and will not deal with the substantive ethical
issues such as how should the risks and inconveniences imposed
on research participants correlate with the ability to give an
informed consent.
CRITERIA OF PROCEDURAL STRINGENCY OF ETHICAL REVIEW
The assessment of procedural stringency of ethical review is
based on the following questions:
1. What is the scope of ethical review and what research
projects are exempted from the review procedure? What is
the possibility of expedited review? For example, human
behavioural science research projects that do not exceed a so-
called minimal risk threshold to research participants are
reviewed by expedited procedures in Canada and the USA.5 6
2. What are the institutions (RECs of different levels and
institutions other than RECs) involved in the review process?
3. How comprehensive is this process of ethical review? For
example, is it limited to one-time approval or does it also
include on-going monitoring and other additional safeguards?
4. Finally, does the system have the power to make ethical
review legally binding or does it only have the power of
recommendation? This is an important distinction because
legally binding review provides for clear sanctions in case of
non-compliance with the law. Legal regulations are also
applicable country-wide to all the relevant research practices
and institutions rather than just to a single institution as
may be the case with the policy of a particular REC
established at a particular research institution.
THREE CASES OF NON-EQUIVALENT STRINGENCY OF ETHICAL
REVIEW
Clinical drug trials versus other types of clinical research
Consider first the case of non-equivalence between rather strict
regulations of clinical drug trials (CDTs) and relatively weaker
regulations of other types of clinical biomedical research. For
example, clinical drug trials in the Baltic States are reviewed by
RECs and state drug agencies (“competent authorities” as they
are called in The Clinical Trials Directive of 20017), while other
types of clinical research are reviewed by RECs only. In addition,
RECs must be notified about any amendment of the CDTand all
serious adverse events. They also must receive annual study
reports. For almost all other non-drug clinical research, these
safeguards are missing. In Latvia, the gap between the strin-
gency of standards is even wider because there are no legally
binding regulations for ethical review of biomedical research
except for CDTs, research on medical devices (an outcome of the
EU Medical Devices Directive8) and research on the Latvian
population genetic database.9 The situation is further compli-
cated by the fact that Latvia has not yet ratified the Oviedo
Convention.10 In Estonia, which has ratified the convention, all
biomedical research projects should in principle be subjected to
ethical review. However, there are no national regulations on
how this should be implemented in practice (eg, what sanctions
could be applied for non-compliance). Despite the aforemen-
tioned differences, in all three countries, we might in principle
encounter a situation where a phase IV CDT (which is often
directly beneficial to the research participants) might undergo
much more stringent ethical review as compared to a rando-
mised clinical trial of different cardio-surgical interventions or
some risky studies in physiology and sport sciences involving
sleep deprivation.
Another problematic area with respect to ethical review
appears in areas of human research not directly linked to the
biomedicial and health field. Two groups of cases may be
distinguished here: non-biomedical research involving risks to
psychological health and non-biomedical research involving risks
to privacy (eg, disclosure of personal information to the third
parties).
Non-biomedical research that involves risks to psychological
health
Even if the Lithuanian system of ethical review is rather
comprehensive covering all types of research related to human
health,11 sensitive sociological, anthropological or psychological
human research studies that do not directly fall into the area of
biomedicine would not be subjected to any formalised ethical
review. In fact, there are no national regulations, legally binding
or otherwise, in this field of human research. Similar gaps might
also be seen in Latvian and Estonian ethical review systems. For
example, it is likely that studies on sexual practices, suicidal
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tendencies or child abuse, initiated by psychologists and
conducted outside healthcare institutions, would bypass the
ethical review procedures even if they are associated with
significant risks to psychological health. Therefore, if the afore-
mentioned studies were to be reviewed by the RECs, it would be
due to the requirements of research institutions and particular
RECs, scientific journals and or funding institutions, or the
study would be reviewed by a special ethics board established by
a professional association. For example, the Lithuanian Psycho-
logical Association has recently established an ethics committee.
However, the information about the procedures of such a review
and the ethics committee itself is not publicly available.
Non-biomedical research that involves risks to privacy
The lacunae similar to those described in the previous section
can be identified in cases of human research projects involving
risks to privacy and are carried out outside the healthcare
context. This type of research is less likely to be subjected to
ethical review than similar research on medical data or archived
biological material. Ethical review of the latter kind of research is
legally required in Lithuania11 and in some cases in Latvia (eg,
research on the Latvian population genetic database9) and
Estonia (eg, research on the Estonian population genetic data-
base12 and e-health databases13), but in Latvia and Lithuania,
there are no legally binding requirements to conduct ethical
review of non-biomedical research that may involve risks to
privacy. This might be seen as a problem because research that
deals with such sensitive data as criminal record or data on
adoptions may involve threats to privacy comparable to those
related to health data. It should be noted that in the EU coun-
tries, processing of sensitive personal data for research purposes
is subjected to previous checking by data protection authorities
following the provisions of the EU Data Protection Directive.14
However, the Directive does not specifically require the ethical
review of such research projects.
The two aforementioned cases of non-biomedical research
show that the requirements of ethical review of differing strin-
gency in the Baltic States would apply to different types of
human studies depending not on the differences in risks involved
but on whether the research project falls within the scope of
biomedicine. This does not seem to be a problem in the USA
where federal research regulations define the scope of ethical
review for the whole field of human research including non-
biomedical projects (103(b)).15 Similarly, the Swedish Act on the
Ethical Review of Research Involving Humans requires review of
biomedical and non-biomedical research projects, where research
is performed according to a method that aims to affect the
subject physically or psychologically or which involves an
obvious risk of physical or psychological damage to the research
person.16 It would be important to check how the aforemen-
tioned lacunae are dealt with in other European countries.
TYPES OF HUMAN RESEARCH ACCORDING TO INTERNATIONAL
REGULATIONS
To better understand the asymmetries and gaps of ethical review
in the Baltic States mentioned above, let us briefly examine
those international regulations specifically addressing ethical
review of different types of human research.
For the purposes of this paper, we distinguish between several
different categories of research: human research (which includes
biomedical and non-biomedical studies involving human subjects),
narrowly and widely defined biomedical research as well as clinical
drug trials. These terms are helpful for our discussion as they
define the scope of important European and international instru-
ments and guidelines that shape ethical review procedures in the
Baltic States and other European countries. The general frame-
work informing of these definitions and corresponding interna-
tional regulations is summarised in figure 1.
Clinical drug trials (or alternatively, “clinical trials on medic-
inal products for human use”7) represent the most strictly
regulated type of human research. In Europe, the most influen-
tial document providing the uniform regulatory framework of
the CDTs is The Clinical Trials Directive of 2001, a legally
binding document on all EU member states.7 CDTs are an
important sub-category (figure 1, field 1) within the broader field
of biomedical research.
The term biomedical research includes CDTs and covers all
other human research studies in the health field. It extends into
a much wider field of clinical research where different diagnostic,
preventive or therapeutic interventions are tested without the
use of medicinal products. Biomedical research is an important
term in the European context because of another legally binding
European instrument, namely, The Additional Protocol on
Biomedical Research to the Convention on Human Rights and
Biomedicine.17 The Protocol, however, is based on a narrow
definition of biomedical research as it only covers research
projects “in the health field” that include “physical intervention”
or “any other intervention as long as it involves a risk to the
Figure 1 Relationship between
different types of human research and
the international regulatory framework. Field 1
CDTs
Field 2
Research in the health
field involving physical 
interventions
interventions that involve risks 
to psychological health
Field 3
Research on health data and 
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psychological health of the person concerned”17: Art. 2 (figure 1,
field 2), which means that such important areas of non-clinical
research as research on archived biological material as well as
research on personal data do not fall within its scope.
The two aforementioned types of non-clinical biomedical
research (figure 1, field 3) have been specifically addressed by
other European documents. For example, research on archived
biological material has been addressed by a Council of Europe
Recommendation,18 while research on personal data has been
covered by the EU Data Protection Directive.14 These fields of
research are also included into the scope of such well-known
international guidelines as WMA Helsinki Declaration (which
covers “medical research involving human subjects, including
research on identifiable human material and data”19: Para 1) and
CIOMS guidelines (which covers “both medical and behavioural
studies pertaining to human health”20: Preamble). Helsinki and
CIOMs guidelines employ a wide definition of biomedical
research as their scope covers fields 1, 2 and 3 (see figure 1). It is
important to note that all the aforementioned regulations are
not legally binding recommendations except for the EU Data
Protection Directive.14 However, the Directive does not provide
specific provisions on ethical review. Therefore, it is important
to note that the field 3 of non-clinical research is in principle less
strictly regulated as compared to the fields 1 and 2 (areas of
narrowly defined biomedical research).
Finally, human research studies that do not fall within the
field of biomedical research (non-biomedical studies) are the least
regulated examples of human research on the European and
international level (see the most peripheral field 4 in figure 1).
There are no binding European regulations covering, for
example, sociological or psychological human studies. Usually,
these types of human research are left to the self-regulatory
mechanisms of universities, professional organisations and
scientific journals.
THE SOURCES OF NON-EQUIVALENT STRINGENCY
Having distinguished between different types of human research
and having articulated criteria of procedural stringency of ethical
review, we now introduce a more systematic analysis of non-
equivalent stringency of ethical review in the Baltic States and
make some related observations. First, there should be equiva-
lent stringency of ethical review within the area of narrowly
defined biomedical research (ie, between figure 1 fields 1 and 2)d
similarly stringent procedures should be applied to CDTs and
other types of clinical research that involve physical intervention
and risks because the general levels of risk of CDTs and other
types of clinical research are similar. We assume that this
asymmetry arises because The Clinical Trials Directive7 is
a binding European instrument requiring adoption of the direc-
tive into the national law. All the EU Member States including
the New Member States have had to harmonise their clinical
drug trials legislation when joining the EU. Regulations related
to all other kinds of biomedical research are much less likely to
be backed by legally binding instruments. Even if ethical review
of biomedical research is supposed to be brought into greater
harmony by the Additional Protocol,17 so far, very few European
countries have ratified the Protocol (as of September 2009, only
five Council of Europe member states, none of Baltic States, have
ratified it).
There should also be equivalence between certain types of
biomedical and non-biomedical research because stringency of
review of research involving risks to psychological health and
risks to privacy should depend on the extent of risk rather than
on whether that research falls within the scope of biomedical
research. With regard to research involving risks to psychological
health, equivalence is needed between certain types of research
within figure 1 fields 4 and 2. One should note here that ratifi-
cation of the Additional Protocol17 by individual member states
tends to increase this stringency gap because its scope only
covers the health field.
The non-equivalence between fields 4 and 3 is of a different
kind because research on personal data and archived biological
material (those studies that do not fall within the confines of
figure 1 field 2dnarrowly defined biomedical research) is not
related to the same risk of harm and inconveniences as one that
involves physical or psychological intervention. However, here,
the asymmetry between biomedical and non-biomedical studies
also exists. Therefore, it also seems that there should be equiv-
alence between certain divisions within figure 1 fields 3 and 4;
that is, between a part of widely defined biomedical research
that does not involve physical interventions and risks to
psychological health and those non-biomedical studies that do
not involve considerable immediate psychological risks but
involve risks to privacy.
ATTEMPTS TO COMPENSATE FOR NON-EQUIVALENT
STRINGENCY OF ETHICAL REVIEW
Even in the absence of national regulations that set uniform
standards of ethical review in the country, the procedures of
ethical review may be enforced by “softer” mechanisms or regu-
lationsdfor example, policy statements/guidelines issued by
RECs themselves, the requirements of different funding bodies or
publishing policies of medical journals that require proof of REC
approval as a condition of acceptance of a paper for publication.
However, it should be noted that the policy of a particular REC
may only extend to research projects carried out in that particular
institution, as is the case in Estonia and Latvia.
This combination of legal and other types of regulations could
provide a sufficient basis for enforcing a policy of ethical review
of different types of human research especially in the countries
with longer traditions of ethical review. However, at the same
time, different standards of ethical review for different types of
research make the effectiveness of ethical review contingent on
local circumstances which in case of the transition societies
might not always provide research participants with sufficient
protection. Ashcroft notes that ethics committees in Eastern
Europe may sometimes be established “more to satisfy foreign
partners’ or research sponsors’ requirements, rather than to
address problems of concern to patients.” (p. 230)2 The problem
is that the countries which have only recently established the
institutions of ethical review might lack the “softer” mecha-
nisms of regulations that ensure all types of human research
being reviewed by RECs or these mechanisms might appear to
be too weak to facilitate the change of practice.
CONCLUDING REMARKS
Apparently, systems of ethical review of human research in the
Baltic States are not based on established and comprehensive
rules covering all types of research projects. Rather, a mixture of
different social regulations applies to different types of human
research. This analysis revealed some systematic features of
ethical review and protection of research participants by (1)
showing how international and European guidelines and legal
standards are being applied in societies where the tradition of
institutionalised ethical review is rather recent and (2) pointing
out areas of weakness in the framework of ethical review of
human research on the European level.
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Variations of the binding force of the international human
research regulations provide at least partial explanation of
existing examples of non-equivalent stringency of ethical review.
The phenomenon of asymmetry between different types of
clinical research is mostly connected to the patchwork-like
nature of different European instruments that regulate different
types of research studies. We think that in this respect, more
harmonisation is needed in Europe. In case of non-biomedical
human research, “softer mechanisms” described above may at
least in part compensate for the lack of more systematic provi-
sions. However, it is important to make sure that stringency of
ethical review depends not on whether research is conducted in
the health field, but on the nature of risks involved.
The “diagnosis” of some examples of systematic non-equiva-
lence suggests the need to implement a consistent system of
regulations for all types of human research. However, we do not
intend to claim that this problem should be solved by introducing
legal regulations of ethical review of the same stringency as
applied to the CDTs or that non-biomedical human research be
treated in the same procedural way as biomedical research.
Caution should be applied to ensure that harmonisation does not
result in over-regulation, which is also possible in this field. For
example, see recent public consultation paper issued by European
Commission that discusses whether The Clinical Trials Directive7
has resulted in over-regulation.21 Some other, perhaps less strin-
gent solution might be preferable. However, first it is important
to recognise that current system of ethical review is susceptible to
non-equivalent stringency of ethical review.
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